Taro Pharma (TARO) Misses Q2 EPS by 36c

Taro Pharma (NYSE: TARO) reported Q2 EPS of $0.66, $0.36 worse than the analyst estimate of $1.02. Revenue for the quarter came in at $132 million versus the consensus estimate of $153.23 million.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• S&P 500 may pull back before midterms, but Citi says buy the dip
• BofA says momentum style supported by earnings revisions